Sanofi

Research Sanofi (SNW) on Bullrun: market cap EUR 94.12B, P/E 24.2, dividend yield 5.3%. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is EUR 94.12B; P/E is 24.2; dividend yield is 5.3%.

Peer valuation comparison

Latest P/E is 24.25x versus a Healthcare sector median of 24.46x.

Latest dividend yield is 5.33% versus a Healthcare sector median of 2.11% (152.6% above).

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025EUR 43.63BEUR 7.85BEUR 7.21B77.2%6.37EUR 7.66BEUR 14.25BEUR 71.38B
FY2024EUR 41.08BEUR 5.62Bn/a75.7%4.43EUR 7.44BEUR 11.79BEUR 77.51B
FY2023EUR 37.82BEUR 5.44Bn/a76.7%4.3EUR 8.71BEUR 14.35BEUR 74.04B
FY2022EUR 37.65BEUR 8.48Bn/a76.2%6.66EUR 12.74BEUR 14.86BEUR 75.15B

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-24EUR 94.12B24.25.2%4.12

Dividend history

Latest trailing dividend snapshot: annual dividend/share 4.12 EUR, yield 5.3%.

YearDividends/share
FY20253.92 EUR
FY20243.76 EUR
FY20233.56 EUR
FY20223.33 EUR

About Sanofi

Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines.

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Sanofi's market cap?

Sanofi's market capitalization is EUR 94.12B.

What is Sanofi's P/E ratio?

Sanofi's price-to-earnings (P/E) ratio is 24.2.

Does Sanofi pay a dividend?

Sanofi has a dividend yield of 5.3%.

What does Sanofi do?

Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc.